Phase I dose-escalating study to evaluate the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of Foxy-5 in patients with metastatic breast, colorectal, or prostate cancer.
Peter Grundtvig Soerensen
Research Funding - WatResearch
Tommy Andersson
Employment or Leadership Position - WntResearch
Stock Ownership - WatResearch (I); WntResearch
Research Funding - WntResearch
Ulla Buhl
Employment or Leadership Position - WntResearch (I); WntResearch
Stock Ownership - WatResearch (B)
Tine Moelvadgaard
Employment or Leadership Position - Smerud Medical Research
Peter Buhl Jensen
Employment or Leadership Position - WntResearch (B)
Stock Ownership - WntResearch (B)
Nils Brunner
Employment or Leadership Position - WatResearch
Stock Ownership - WntResearch
Dorte Nielsen
Consultant or Advisory Role - WntResearch